Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

European Journal of Cancer

Volumn 47, Issue 16, 2011, Pages 2387-2395

  Pivot, Xavier ^a   Schneeweiss, Andreas ^b   Verma, Shailendra ^c   Thomssen, Christoph ^d   Passos Coelho, José Luis ^e   Benedetti, Giovanni ^f   Ciruelos, Eva ^g   Von Moos, Roger ^h   Chang, Hong Tai ⁱ   Duenne, Anja Alexandra ^j   Miles, David W ^k  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^f Oncology Hospital of Macerata   (Italy)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

ⁱ KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k MOUNT VERNON CANCER CENTRE   (United Kingdom)

more..

Author keywords

Bevacizumab; Docetaxel; Elderly; Metastatic breast cancer; Taxane

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; DOCETAXEL; PLACEBO; TAXANE DERIVATIVE;

ABSCESS; AGED; ANTIHYPERTENSIVE THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; EPISTAXIS; FEBRILE NEUTROPENIA; FISTULA; GERIATRIC DISORDER; HUMAN; HYPERTENSION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; RESPIRATORY FAILURE; SEPTIC SHOCK; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TAXOIDS;

EID: 80054883209     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.018     Document Type: Article

References (39)

1. M. Extermann Treating advanced breast cancer in the older woman Oncology 20 2009 1355 1360
2. C.E. Holmes, and H.B. Muss Diagnosis and treatment of breast cancer in the elderly CA Cancer J Clin 53 2003 227 244 (Pubitemid 37045791)
3. S.G. Diab, R.M. Elledge, and G.M. Clark Tumor characteristics and clinical outcome of elderly women with breast cancer J Natl Cancer Inst 92 2000 550 556 (Pubitemid 30212316)
4. S. Eppenberger-Castori, D.H. Moore Jr, and A.D. Thor Age-associated biomarker profiles of human breast cancer Int J Biochem Cell Biol 34 2002 1318 1330 (Pubitemid 35245392)
5. A. Molino, M. Giovannini, and A. Auriemma Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer Crit Rev Oncol Hematol 59 2006 226 233 (Pubitemid 44279421)
6. P. Tran, and I.S. Fentiman Better treatment for breast cancer in older patients Expert Rev Anticancer Ther 9 2009 1081 1090
7. R.W. Carlson, S. Moench, and A. Hurria NCCN Task Force Report: breast cancer in the older woman J Natl Compr Canc Netw 8 Suppl. 4 2008 S1 S25
8. M. Aapro, S. Monfardini, and A. Jirillo Management of primary and advanced breast cancer in older unfit patients (medical treatment) Cancer Treat Rev 35 2009 503 508
9. D. Crivellari, M. Aapro, and R. Leonard Breast cancer and the elderly J Clin Oncol 25 2007 1882 1890
10. L.F. Hutchins, J.M. Unger, and J.J. Crowley Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 1999 2061 2067 (Pubitemid 30035956)
11. Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005; CD003372.
12. A. Chan, D. Miles, and X. Pivot Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer Ann Oncol 21 2010 2305 2315
13. D.W. Miles, A. Chan, and L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3229 3247
14. X. Pivot, S. Verma, and C. Thomssen Clinical benefit of bevacizumab (BV) + first-line docetaxel (D) in elderly patients (pts) with locally-recurrent (LR) or metastatic breast cancer (MBC): AVADO study J Clin Oncol 27 15 2009 1094
15. J.A. Foster, G.D. Salinas, and D. Mansell How does older age influence oncologists' cancer management? Oncologist 15 2010 584 592
16. A. Brunello, A. Roma, and C. Falci Chemotherapy and targeted agents for elderly women with advanced breast cancer Recent Pat Anticancer Drug Discov 3 2008 187 201
17. L. Balducci Management of cancer in the elderly Oncology 20 2006 135 143 (Pubitemid 46931060)
18. S. Monfardini Prescribing anti-cancer drugs in elderly cancer patients Eur J Cancer 38 2002 2341 2346 (Pubitemid 35387485)
19. G.W. Sledge, D. Neuberg, and P. Bernardo Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 2003 588 592 (Pubitemid 46621890)
20. R. Jones, and R.C.F. Leonard Treating elderly patients with breast cancer Breast Cancer Online 8 4 2005 [ www.bco.org ]
21. L. Charnelda, C.L. Gray, and C. Gardner Adverse drug events in the elderly: an ongoing problem J Manag Care Pharm 15 2009 568 571
22. R. Gray, S. Bhattacharya, and C. Bowden Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer J Clin Oncol 27 2009 4966 4972
23. J. O'Shaughnessy, V. Diéras, and J. Glaspy Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer Cancer Res 69 2009 512s [Abstract 207]
24. N.J. Robert, V. Dieras, and J. Glaspy Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
25. J. Glaspy, V. Dieras, and A. Brufsky Bevacizumab in combination with chemotherapy in the treatment of HER2-metastatic breast cancer: PFS subgroup results from two phase III studies Eur J Cancer Suppl 8 2010 202
26. L. Biganzoli, H. Cortes-Funes, and C. Thomssen Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study J Clin Oncol 27 2009 48s [abstract 1032]
27. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2010 [Epub ahead of print].
28. K.R. Broglio, and D.A. Berry Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 2009 1642 1649
29. L. Biganzoli, T. Cufer, and P. Bruning Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research J Clin Oncol 20 2002 3114 3121 (Pubitemid 34791101)
30. P.A. Cassier, S. Chabaud, and V. Trillet-Lenoir A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study Breast Cancer Res Treat 109 2008 343 350 (Pubitemid 351658936)
31. J. Jassem, T. Pienkowski, and A. Pluzanska Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Onkologie 32 2009 468 472
32. J.M. Nabholtz, C. Falkson, and D. Campos Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial Br J Cancer 91 2004 968 975
33. J.U. Blohmer, P. Schmid, and J. Hilfrich Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial Ann Oncol 21 2010 1430 1435
34. P.F. Conte, V. Guarneri, and P. Bruzzi Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial Cancer 101 2004 704 712 (Pubitemid 39030924)
35. R.E. Langley, J. Carmichael, and A.L. Jones Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer. United Kingdom National Cancer Research Institute trial AB01 J Clin Oncol 23 2005 8322 8330
36. K.S. Albain, S.M. Nag, and G. Calderillo-Ruiz Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol 26 2008 3950 3957
37. J. Jassem, T. Pieńkowski, and A. Płuzańska Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial J Clin Oncol 19 2001 1707 1715 (Pubitemid 32230871)
38. E. Baldini, T. Prochilo, and B. Salvadori Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety Br J Cancer 91 2004 45 49 (Pubitemid 39013043)
39. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2008. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site; 2011.